New CHIME, AMDIS agreement furthers strategic partnership

The College of Healthcare Information Management Executives (CHIME) has a new agreement to provide management services to the Association of Medical Directors of Information Systems (AMDIS).

Under the terms of the management services agreement, CHIME will provide operational, administrative and staff support to AMDIS in the areas of educational programming, event management, public policy, marketing/communications and industry relations. The new agreement will also provide the CMIO and senior informatics executive members of AMDIS access to CHIME affiliate-level membership and professional development opportunities.

As part of the agreement, CHIME has appointed William F. Bria, MD as its new executive vice president of medical informatics and patient safety, who will serve as the liaison between both organizations and assist in providing strategic direction to AMDIS. Bria will retain his role as chair of the AMDIS Board of Advisors.

The agreement, approved by both boards, follows the formation of a strategic alliance announced in July of last year, intended to enhance collaboration between the two industry associations and provide cross-lateral support to their respective members in the progression of healthcare IT adoption and implementation.

 

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.